5 Key Takeaways
-
1
Sight Sciences announced the commercial availability of OMNI Ultra ahead of its debut at the 2026 American Academy of Ophthalmology Annual Meeting.
-
2
OMNI Ultra combines canaloplasty and trabeculotomy in one implant-free device designed to reduce intraocular pressure in adults with primary open-angle glaucoma.
-
3
The system enables circumferential canaloplasty in a single pass, followed by trabeculotomy, and is designed to address resistance in the trabecular meshwork, Schlemm's canal, and collector channels.
-
4
TruSync Plus automatically delivers viscoelastic during microcatheter advancement and retraction, while enhanced catheter visualization is intended to improve visibility and control.
-
5
OMNI Ultra can be used alone or with cataract surgery through a clear corneal microincision, without leaving an implant in the eye.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
